What is the recommended treatment approach for a patient with blast crisis of acute myeloid leukemia?

Blast Crisis with Acute Myeloid Leukemia: Treatment Approach

For patients presenting with what appears to be "blast crisis" in the context of AML, you must first clarify the diagnosis—true blast crisis occurs in chronic myeloid leukemia (CML), not de novo AML, though the term is sometimes misused to describe high blast counts in AML.

Critical Diagnostic Distinction

The terminology "blast crisis with AML" requires immediate clarification:

• If this is CML in myeloid blast phase (MBP-CML): This represents transformation of chronic phase CML with ≥20% blasts in blood or marrow 1, 2
• If this is de novo AML with high blast burden: This is simply AML requiring standard risk-stratified treatment
• If this is refractory/relapsed AML: This represents treatment failure requiring salvage approaches

Treatment for CML Myeloid Blast Crisis

For confirmed CML in myeloid blast phase, initiate a third-generation tyrosine kinase inhibitor (TKI) immediately, with or without intensive chemotherapy, followed by allogeneic stem cell transplantation if feasible 1, 2.

Specific Treatment Algorithm for MBP-CML:

1. Immediate TKI initiation 1, 2:

   • Third-generation TKI (ponatinib if T315I mutation present, or newer agents like orelabatinib) 3, 2
   • Second-generation TKI (dasatinib or nilotinib) if third-generation unavailable
   • Check BCR-ABL1 mutation status to guide TKI selection

2. Consider adding intensive chemotherapy 1, 2:

   • AML-type induction (7+3: cytarabine 100-200 mg/m² × 7 days + daunorubicin 60-90 mg/m² × 3 days) combined with TKI
   • TKI monotherapy may be considered in patients unfit for intensive therapy

3. Proceed to allogeneic transplant 1:

   • AlloHCT should be offered before disease becomes fully blastic
   • This is the only potentially curative option for MBP-CML
   • Transplant should occur as soon as donor identified and disease controlled

Expected Outcomes:

The prognosis for MBP-CML remains poor despite TKI therapy, with responses less durable than chronic phase CML 1, 2. However, cases achieving molecular remission with TKI therapy have been reported 3.

Treatment for De Novo AML (If Misdiagnosed as "Blast Crisis")

If this is actually de novo AML with high blast counts (not CML transformation), treat according to risk stratification and patient fitness 4.

For Fit Patients Eligible for Intensive Therapy:

Risk-stratified approach 4:

1. Core binding factor (CBF) AML: 7+3+GO (gemtuzumab ozogamicin if CD33+) [I, A] 4

2. Therapy-related or MDS-related AML (age ≥60): CPX-351 (liposomal daunorubicin/cytarabine) [I, A] 4

3. FLT3-mutated AML: 7+3+midostaurin [I, A] 4

4. All other AML: Standard 7+3 induction [II, A] 4

For Unfit/Elderly Patients:

Use lower-intensity therapy 5:

• Hypomethylating agents (azacitidine or decitabine) preferred [II, B]
• Low-dose cytarabine alternative
• Best supportive care if extremely frail

Treatment for Refractory/Relapsed AML

If this represents primary refractory or relapsed AML (treatment failure), proceed directly to allogeneic transplant if donor available; otherwise, consider salvage chemotherapy or clinical trial 5.

Specific Salvage Approach 5:

1. With HLA-matched donor available: Proceed directly to alloHCT [II, B]

   • Limited success but only curative option
   • Considerable morbidity expected

2. Without donor or transplant-ineligible:

   • Clinical trial preferred
   • Salvage chemotherapy (HiDAC-based if not previously used)
   • Best supportive care if deteriorated

3. Prognosis: Dismal regardless of treatment attempts 5

Critical Pitfalls to Avoid

• Do not confuse CML blast crisis with de novo AML: Check for BCR-ABL1 fusion gene and Philadelphia chromosome 1, 6, 3
• Do not delay TKI in confirmed CML blast phase: Start immediately while awaiting mutation analysis 2
• Do not use AML chemotherapy alone for MBP-CML: TKI must be included 1, 2
• Do not delay transplant evaluation: Outcomes worsen significantly once fully blastic 1
• For hyperleukocytosis (WBC >100,000): Consider leukapheresis or hydroxyurea for cytoreduction before definitive therapy 7

Monitoring Response

• For MBP-CML: Check BCR-ABL1 transcript levels at 2 weeks to assess TKI efficacy 3
• For AML: Bone marrow assessment at days 14-21 after induction 8
• Measurable residual disease (MRD) monitoring guides consolidation decisions 9